<DOC>
	<DOCNO>NCT01168973</DOCNO>
	<brief_summary>The purpose study compare survival participant receive chemotherapy ramucirumab versus chemotherapy alone second line treatment NSCLC prior first line platinum-based chemotherapy .</brief_summary>
	<brief_title>A Study Chemotherapy Ramucirumab Versus Chemotherapy Alone Second Line Non-Small Cell Lung Cancer ( NSCLC ) Participants Who Received Prior First Line Platinum-based Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Ramucirumab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Disease progression one prior firstline platinumbased chemotherapy without maintenance therapy Prior bevacizumab firstline and/or maintenance therapy allow Signed inform consent Eastern Cooperative Oncology Group ( ECOG ) performance status 01 Histologically cytologically confirm NSCLC Stage IV NSCLC disease Participants measurable nonmeasurable disease Adequate organ function , define : Total bilirubin less equal Upper Limit Normal ( ULN ) , Aspartate Aminotransferase ( AST ) Alanine Aminotransaminase ( ALT ) less equal 2.5 x ULN , less equal 5 x ULN transferase elevation due liver metastasis , Serum creatinine less equal 1.5 x ULN calculate creatinine clearance great equal 50 milliliter per minute ( ml/min ) ( per CockcroftGault formula equivalent and/or 24hour urine collection ) , Absolute Neutrophil Count ( ANC ) great equal 1.5 x 10^3/microliters ( µL ) , hemoglobin great equal 10.0 grams/deciliter ( g/dL ) , platelet great equal 100 x 10^3/µL , Adequate coagulation function define International Normalized Ratio ( INR ) less equal 1.5 , prothrombin time partial thromboplastin time le equal 1.5 x ULN . The participant cirrhosis level ChildPugh B ( bad ) cirrhosis ( degree ) history hepatic encephalopathy clinically meaningful ascites result cirrhosis . Clinically meaningful ascites define ascites result cirrhosis require ongoing treatment diuretic and/or paracentesis . Urinary protein less equal 1+ dipstick routine urinalysis . If urine dipstick routine analysis indicate proteinuria great equal 2+ , 24hour urine must collect must demonstrate less 1000 milligram ( mg ) protein . Participants reproductive potential ( sex ) must agree use reliable method birth control ( hormonal barrier method ) study period least 12 week last dose study therapy Life expectancy great equal 3 month Prior radiation therapy allow : In case chest radiotherapy least 28 day elapse completion radiation treatment prior randomization ; In case focal palliative radiation treatment least 7 day elapse last radiation treatment prior randomization ( provide 25 % less total bone marrow irradiate ) ; In case Central Nervous System ( CNS ) radiation least 14 day elapse completion radiation treatment prior randomization Disease progression 1 prior chemotherapy regimens Participants whose prior treatment tyrosine kinase inhibitor The participant 's tumor wholly partially contain small cell lung cancer Major surgery within 28 day prior randomization , subcutaneous venous access device placement within 7 day prior randomization . Postoperative bleeding complication wind complication surgical procedure perform last 2 month . Concurrent treatment anticancer therapy , include chemotherapy , immunotherapy , hormonal therapy , chemoembolization , target therapy Last dose bevacizumab must least 28 day time randomization Last dose cytotoxic chemotherapy must least 14 day time randomization The participant untreated CNS metastasis . Participants treat brain metastasis eligible clinically stable regard neurologic function , steroid cranial irradiation end least 2 week prior randomization , surgical resection perform least 28 day prior randomization . No evidence Grade great equal 1 CNS hemorrhage base pretreatment Magnetic Resonance Imaging ( MRI ) IV contrast Computed Tomography ( CT ) scan . Radiologically document evidence major blood vessel invasion encasement cancer Radiographic evidence intratumor cavitation History uncontrolled hereditary acquire thrombotic disorder Chronic therapy nonsteroidal antiinflammatory drug ( NSAIDs ) antiplatelet agent ; Aspirin use dose 325 milligram per day ( mg/day ) permit History gross hemoptysis ( define bright red blood great equal 1/2 teaspoon ) within 2 month prior randomization Clinically relevant congestive heart failure [ New York Heart Association ( NYHA IIIV ) ] symptomatic poorly control cardiac arrhythmia Any arterial thrombotic event , include myocardial infarction , unstable angina , cerebrovascular accident , transient ischemic attack , within 6 month prior randomization Uncontrolled arterial hypertension great equal 150 / great equal 90 millimeter mercury ( mm Hg ) despite standard medical management Serious nonhealing wound , ulcer , bone fracture within 28 day prior randomization Significant bleeding disorder , vasculitis , Grade 3/4 gastrointestinal bleeding within 3 month prior randomization Gastrointestinal ( GI ) perforation and/or fistula within 6 month prior randomization Bowel obstruction , history presence inflammatory enteropathy extensive intestinal resection Crohn 's disease , ulcerative colitis , chronic diarrhea Peripheral neuropathy great equal Grade 2 [ National Cancer Institute Common Terminology Criteria Adverse Events ( NCICTCAE ) version 4.02 ] Serious illness medical condition ( ) include , limited : Human immunodeficiency virus ( HIV ) infection acquire immunodeficiency syndrome ( AIDS ) relate illness ; Active uncontrolled clinically serious infection ; Severe acute chronic medical psychiatric condition laboratory abnormality may increase risk associate study participation study drug administration Known allergy hypersensitivity reaction treatment components The participant pregnant breastfeeding Current recent ( within 28 day prior randomization ) treatment investigational drug device receive regulatory approval indication time randomization , participation another interventional clinical trial Prior therapy docetaxel</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>second line</keyword>
	<keyword>non small cell lung cancer</keyword>
	<keyword>NSCLC</keyword>
	<keyword>phase 3</keyword>
	<keyword>ramucirumab</keyword>
	<keyword>lung cancer</keyword>
	<keyword>docetaxel</keyword>
	<keyword>taxotere</keyword>
</DOC>